- Home
- LDI vs ENGN Comparison
LDI vs ENGN Comparison
Compare LDI & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDI
- ENGN
- Stock Information
- Founded
- LDI 2010
- ENGN 1999
- Country
- LDI United States
- ENGN Canada
- Employees
- LDI N/A
- ENGN N/A
- Industry
- LDI Finance: Consumer Services
- ENGN
- Sector
- LDI Finance
- ENGN
- Exchange
- LDI Nasdaq
- ENGN Nasdaq
- Market Cap
- LDI 221.2M
- ENGN 191.1M
- IPO Year
- LDI 2021
- ENGN N/A
- Fundamental
- Price
- LDI $3.55
- ENGN $5.29
- Analyst Decision
- LDI Sell
- ENGN Buy
- Analyst Count
- LDI 3
- ENGN 7
- Target Price
- LDI $2.30
- ENGN $23.29
- AVG Volume (30 Days)
- LDI 4.0M
- ENGN 170.9K
- Earning Date
- LDI 11-04-2025
- ENGN 09-09-2025
- Dividend Yield
- LDI N/A
- ENGN N/A
- EPS Growth
- LDI N/A
- ENGN N/A
- EPS
- LDI N/A
- ENGN N/A
- Revenue
- LDI $1,124,074,000.00
- ENGN N/A
- Revenue This Year
- LDI $21.95
- ENGN N/A
- Revenue Next Year
- LDI $15.72
- ENGN N/A
- P/E Ratio
- LDI N/A
- ENGN N/A
- Revenue Growth
- LDI 27.06
- ENGN N/A
- 52 Week Low
- LDI $1.01
- ENGN $2.65
- 52 Week High
- LDI $3.23
- ENGN $11.00
- Technical
- Relative Strength Index (RSI)
- LDI 84.05
- ENGN 81.37
- Support Level
- LDI $1.81
- ENGN $4.24
- Resistance Level
- LDI $2.16
- ENGN $3.89
- Average True Range (ATR)
- LDI 0.23
- ENGN 0.37
- MACD
- LDI 0.12
- ENGN 0.11
- Stochastic Oscillator
- LDI 78.38
- ENGN 95.55
About LDI loanDepot Inc.
loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It also provides online mortgage loans for refinancing and home purchases. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.